Shinichi Oka

TL;DR: No associations with mortality were found with any circulating miRNAs studied and these results cast doubt onto the effectiveness of circulating miRNA as early predictors of mortality or the major underlying diseases that contribute to mortality in participants treated for HIV-1 infection.

TL;DR: This process of viral adaptation may dismantle the well-established HLA associations with control of HIV infection that are linked to the availability of key epitopes, and highlights the challenge for a vaccine to keep pace with the changing immunological landscape presented by HIV.

TL;DR: EFV dose could be decreased in those patients harboring the genotype of CYP2B6 to reduce toxicity with compromising potency, representing the first step of the Tailor-Made therapy of HIV-1 infection.

TL;DR: Genotype-based EFV dose reduction is feasible in CYP2B6 *6 /*6 and *6/*26 carriers, which can reduce EFV-associated CNS symptoms, and CNS-related symptoms improved with dose reduction in 10 of the 14 patients, although some had not been aware of the symptoms at initial dosage.

TL;DR: Therapy with long-acting cabotegravir plus rilpivirine was noninferior to oral therapy with dolutegravIR-abacavir-lamivudine with regard to maintaining HIV-1 suppression.